A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) Academic Article uri icon


MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Glioblastoma
  • Neoplasm Recurrence, Local


  • Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial. The primary endpoint was radiographic response rate. Secondary endpoints included progression-free survival and correlation of molecular profiles with treatment response. 36% of patients had stable disease and 14% a partial response; however, responses were not durable and only one patient was progression-free at six months. Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects. EGFR and PTEN status did not clearly predict response to treatment.

publication date

  • January 2009



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1007/s11060-008-9741-z

PubMed ID

  • 19018475

Additional Document Info

start page

  • 99

end page

  • 105


  • 92


  • 1